

[94] DREAMED DIABETES

Oranit Ido¹, Eran Atlas¹, ¹ Shimon 3

- **Investment Rational**

Advisor- CE- Marked Cloud-based algorithm providing decision support system for physicians and patients on insulin dosing recommendations. DreaMed partner with Glooko, a DMS leader for patient with diabetes. Global market for diabetes management products stands at \$41 billion.

DreaMed's multidisciplinary team includes thought-leading endocrinologists and engineers that developed the first ever CE-marked artificial pancreas technology was licensed to Medtronic Diabetes

- **Business Strategy**

DreaMed is focusing on B-B service PPPM model intending of using Glooko and other partners as re-sellers of our technology.

- **Core Technology**

Advisor cognitive technology analyzes all available real-world data on insulin dosing and blood glucose (sensor readings, fingerstick measurements, meal or carb intake data), in addition to patient reporting. With fuzzy logic and adaptive learning algorithms, MD Logic emulates the way expert endocrinologists actually evaluate their patients, progressively refining their understanding of each case – but with faster analysis and deeper insights.

- **Product Profile/Pipeline**

Advisor portfolio- Cloud-based algorithm providing decision support system for physicians and patients on insulin dosing recommendations. Advisor will help different types of needs for different types of populations depending on their insulin therapy. Advisor first service for type 1 and insulin pump patients got CE mark and intend to be launch through Glooko in the summer.

- **What's Next?**

DreaMed is focusing on improving Advisor abilities to patients with type 1 diabetes under multiple daily injections and patients with type 2 diabetes. Multicenter study with Advisor for HCPs is under way with expected results by end of 2018. Round C is planed for end of year.